Thromboembolic risk in the patient with heart failure

Article
First Online:

Opinion statement

Although heart failure is a procoagulant state, the incidence of arterial thromboembolism (peripheral arterial emboli and strokes) is relatively low in the outpatient setting and seems to be higher in those with concomitant atrial fibrillation or recent large anterior myocardial infarction, especially in the presence of a dyskinetic apex. Hospitalized heart failure patients, on the other hand, have an extremely high rate of deep venous thrombosis and pulmonary emboli. Outpatients with heart failure should receive anticoagulation only in the presence of atrial fibrillation or if they have experienced a prior embolic event. Patients with recent large anterior infarction or recent infarction with documented thrombus should be treated with anticoagulation for the initial 3 months after the infarct, whereas those with evidence of a mural thrombus should receive anticoagulation at least until the thrombus has resolved. Heart failure patients with ischemic cardiomyopathy should receive antiplatelet agents for the prevention of myocardial infarction, stroke, or death. Antiplatelet agents should not be prescribed for heart failure patients with nonischemic cardiomyopathy or without other evidence of atherosclerotic vascular disease. All hospitalized heart failure patients who are not taking oral anticoagulants should receive prophylaxis with low molecular weight heparins or factor Xa inhibitors.

Keywords

Warfarin Clopidogrel Enoxaparin Heart Failure Patient Venous Thromboembolism 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Rosamond W, Flegal K, Friday G, et al.: Heart disease and stroke statistics-2007 Update. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007, 115:e69–e171.PubMedCrossRefGoogle Scholar
  2. 2.
    Jafri SM, Ozawa T, Mammen E, et al.: Platelet function, thrombin and fibrinolytic activity in patients with heart failure. Eur Heart J 1993, 14:205–212.PubMedGoogle Scholar
  3. 3.
    Yamamoto K, Ikeda U, Furuhashi K, et al.: The coagulation system is activated in idiopathic cardiomyopathy. J Am Coll Cardiol 1995, 25:1634–1640.PubMedCrossRefGoogle Scholar
  4. 4.
    Lip GYH, Gibbs CR: Does heart failure confer a hypercoagulable state? J Am Coll Cardiol 1999, 33:1424–1426.PubMedCrossRefGoogle Scholar
  5. 5.
    Katz SD, Hryniewicz K, Hriljac I, et al.: Vascular endothelial dysfunction and mortality risk in patients with chronic heart failure. Circulation 2005, 111:310–314.PubMedCrossRefGoogle Scholar
  6. 6.
    Belch JJ, Lowe GD, Ward AG, et al.: Prevention of deep vein thrombosis in medical patients by low-dose heparin. Scott Med J 1981, 26:115–117.PubMedGoogle Scholar
  7. 7.
    Samama MM, Cohen AT, Darmon JY, et al.: A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 1999, 341:793–800.PubMedCrossRefGoogle Scholar
  8. 8.
    Alikhan R, Cohen AT, Combe S, et al.: Risk factors for venous thromboembolism in hospitalized patients with acute medical illness. Analysis of the MEDENOX study. Arch Intern Med 2004, 164:963–968.PubMedCrossRefGoogle Scholar
  9. 9.
    Beemath A, Stein PD, Skaf E, et al.: Risk of venous thromboembolism in patients hospitalized with heart failure. Am J Cardiol 2006, 98:793–795.PubMedCrossRefGoogle Scholar
  10. 10.
    Beemath A, Skaf E, Stein PD: Pulmonary embolism as a cause of death in adults who died with heart failure. Am J Cardiol 2006, 98:1073–1075.PubMedCrossRefGoogle Scholar
  11. 11.
    Darze ES, Latado AL, Guimaraes AG, et al.: Incidence and clinical predictors of pulmonary embolism in severe heart failure patients admitted to a coronary care unit. Chest 2005, 128:2576–2580.PubMedCrossRefGoogle Scholar
  12. 12.
    Ogren M, Bergqvist D, Eriksson H, et al.: Prevalence and risk of pulmonary embolism in patients with intracardiac thrombosis: a population-based study of 23 796 consecutive autopsies. Eur Heart J 2005, 26:1108–1114.PubMedCrossRefGoogle Scholar
  13. 13.
    Fuster V, Gersh BJ, Giuliani ER, et al.: The natural history of idiopathic dilated cardiomyopathy. Am J Cardiol 1981, 47:525–531.PubMedCrossRefGoogle Scholar
  14. 14.
    Gottdiener JS, Gay JA, Van Voorhees L, et al.: Frequency and embolic potential of left ventricular thrombus in dilated cardiomyopathy. Assessment by 2-dimensional echocardiography. Am J Cardiol 1983, 52:1281–1285.PubMedCrossRefGoogle Scholar
  15. 15.
    Diaz RA, Obasohan A, Oakley CM: Prediction of outcome in dilated cardiomyopathy. Br Heart J 1987, 58:393–399.PubMedGoogle Scholar
  16. 16.
    Ciaccheri M, Castelli G, Cecchi F, et al.: Lack of correlation between intracavitary thrombus detected by cross-sectional echocardiography and systemic emboli in patients with dilated cardiomyopathy. Br Heart J 1989, 62:26–29.PubMedGoogle Scholar
  17. 17.
    Blondheim DS, Jacobs LE, Kotler MN, et al.: Dilated cardiomyopathy with mitral regurgitation: decreased survival despite a low frequency of left ventricular thrombus. Am Heart J 1991, 122:763–771.PubMedCrossRefGoogle Scholar
  18. 18.
    Falk RH, Foster E, Coats MH: Ventricular thrombi and thromboembolism in dilated cardiomyopathy: a prospective follow-up study. Am Heart J 1992, 123:136–142.PubMedCrossRefGoogle Scholar
  19. 19.
    Katz SD, Marantz PR, Biasucci L, et al.: Low incidence of stroke in ambulatory patients with heart failure: a prospective study. Am Heart J 1993, 126:141–146.PubMedGoogle Scholar
  20. 20.
    Natterson PD, Stevenson WG, Saxon LA, et al.: Risk of arterial embolization in 224 patients awaiting cardiac transplantation. Am Heart J 1995, 129:564–570.PubMedCrossRefGoogle Scholar
  21. 21.
    Cioffie G, Pozzoli M, Forni G, et al.: Systemic thromboembolism in chronic heart failure. A prospective study in 406 patients. Eur Heart J 1996, 17:1381–1389.Google Scholar
  22. 22.
    Kyrle PA, Kominger C, Gossinger H, et al.: Prevention of arterial and pulmonary embolism by oral anticoagulants in patients with dilated cardiomyopathy. Thromb Haemost 1985, 54:521–523.PubMedGoogle Scholar
  23. 23.
    Hays AG, Sacco RL, Rundek T, et al.: Left ventricular systolic dysfunction and the risk of ischemic stroke in a multiethnic population. Stroke 2006, 37:1715–1719.PubMedCrossRefGoogle Scholar
  24. 24.
    Heit JA, Silverstein MD, Mohr DN, et al.: Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000, 160:809–815.PubMedCrossRefGoogle Scholar
  25. 25.
    Howell MD, Geraci JM, Knowlton AA: Congestive heart failure and outpatient risk of venous thromboembolism: a retrospective, case-control study. J Clin Epidemiol 2001, 54:810–816.PubMedCrossRefGoogle Scholar
  26. 26.
    Samama MM: An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the SIRIUS study. Arch Intern Med 2000, 160:3415–3420.PubMedCrossRefGoogle Scholar
  27. 27.
    Dunkman WB, Johnson GR, Carson PE, et al.: Incidence of thromboembolic events in congestive heart failure. Circulation 1993, 87(suppl IV):94–101.Google Scholar
  28. 28.
    Dries DL, Rosenberg YD, Waclawiw MA, et al.: Ejection fraction and risk of thromboembolic events in patients with sinus rhythm: evidence of gender difference in the studies of left ventricular dysfunction trial. J Am Coll Cardiol 1997, 29:1074–1080.PubMedCrossRefGoogle Scholar
  29. 29.
    Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators [no authors listed]. Lancet 1993, 342:821–828.Google Scholar
  30. 30.
    Loh E, Sutton MJ, Wun CC, et al.: Ventricular dysfunction and the risk of stroke after myocardial infarction. N Engl J Med 1997, 336:251–257.PubMedCrossRefGoogle Scholar
  31. 31.
    Gibbs CR, Blann AD, Watson RD, et al.: Abnormalities of hemorheological, endothelial, and platelet function in patients with chronic heart failure in sinus rhythm. Circulation 2001, 103:1746–1751.PubMedGoogle Scholar
  32. 32.
    Sbarouni E, Bradshaw A, Andreotti F, et al.: Relationship between hemostatic abnormalities and neuroendocrine activity in heart failure. Am Heart J 1994, 127:607–612.PubMedCrossRefGoogle Scholar
  33. 33.
    Chong AY, Blann AD, Patel J, et al.: Endothelial dysfunction and damage in congestive heart failure: relation of flow-mediated dilation to circulating endothelial cells, plasma indexes of endothelial damage, and brain natriuretic peptide. Circulation 2004, 110:1794–1798.PubMedCrossRefGoogle Scholar
  34. 34.
    Kleber FX, Witt C, Vogel G, et al.: Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. Am Heart J 2003, 145:614–621.PubMedCrossRefGoogle Scholar
  35. 35.
    Leizorovicz A, Cohen AT, Turpie AG, et al.: Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004, 110:874–879.PubMedCrossRefGoogle Scholar
  36. 36.
    Cohen AT, Davidson BL, Gallus AS, et al.: Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomized placebo controlled trial. BMJ 2006, 332:325–329.PubMedCrossRefGoogle Scholar
  37. 37.
    Harvey WP, Finch CA: Dicumarol prophylaxis of thromboembolic disease in congestive heart failure. N Engl J Med 1950, 242:208–211.PubMedCrossRefGoogle Scholar
  38. 38.
    Anderson GM, Hull E: The effect of dicumarol upon the mortality and incidence of thromboembolic complications in congestive heart failure. Am Heart J 1950, 39:697–702.PubMedCrossRefGoogle Scholar
  39. 39.
    Griffiths GC, Stragnell R, Levinson DC, et al.: A study of the beneficial effects of anticoagulant therapy in congestive heart failure. Ann Intern Med 1952, 37:867–887.Google Scholar
  40. 40.
    Al-Khadra AS, Salem DN, Rand WM, et al.: Warfarin anticoagulation and survival: a cohort analysis from the studies of left ventricular dysfunction. J Am Coll Cardiol 1998, 31:749–753.PubMedCrossRefGoogle Scholar
  41. 41.
    Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group [no authors listed]. N Engl J Med 1987, 316:1429–1435.Google Scholar
  42. 42.
    Echemann M, Alla F, Briancon S, et al.: Antithrombotic therapy is associated with better survival in patients with severe heart failure and left ventricular systolic dysfunction (EPICAL study). Eur J Heart Fail 2002, 4:647–654.PubMedCrossRefGoogle Scholar
  43. 43.
    Cleland JG, Findlay I, Jafri S, et al.: The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. Am Heart J 2004, 148:157–164.PubMedCrossRefGoogle Scholar
  44. 44.
    Massie BM, Krol WF, Ammon SE, et al.: The Warfarin and Antiplatelet Therapy in Heart Failure trial(WATCH): rationale, design, and baseline patient characteristics. J Card Fail 2004, 10:101–112.PubMedCrossRefGoogle Scholar
  45. 45.
    Massie BM, Krol WF, Ammon SE, et al.: Final results of the Warfarin and Antiplatelet Therapy in Heart Failure trial (WATCH): a randomized comparison of warfarin, aspirin, and clopidogrel. Paper presented at the Annual Scientific Session of the American College of Cardiology. New Orleans, LA; March 7–10, 2004.Google Scholar
  46. 46.
    Cokkinos DV, Haralabopoulos GC, Kostis JB, et al.: Efficacy of antithrom botic therapy in chronic heart failure: the HELAS study. Eur J Heart Fail 2006, 8:428–432.PubMedCrossRefGoogle Scholar
  47. 47.
    Pullicino P, Thompson JL, Barton B, et al.: Warfarin versus aspirin in patients with reduced cardiac ejection fraction (WARCEF): rationale, objectives, and design. J Card Fail 2006, 12:39–46.PubMedCrossRefGoogle Scholar
  48. 48.
    Al-Khadra AS, Salem DN, Rand WM, et al.: Antiplatelet agents and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction (SOLVD) trial. J Am Coll Cardiol 1998, 31:419–425.PubMedCrossRefGoogle Scholar
  49. 49.
    Nguyen KN, Aursnes I, Kjekshus J: Interaction between enalapril and aspirin on mortality after acute myocardial infarction. Subgroup Anal Cooperative New Scand Enalapril Survival Study II (CONSENSUS II). Am J Cardiol 1997, 15:115–119.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  1. 1.Northwestern University Feinberg School of MedicineChicagoUSA

Personalised recommendations